Managing Biospecimens in Cell and Gene Therapy Trials
Pursuing new tools and capabilities in sample logistics, storage, and data analysis.
A Biosafety Perspective on Operational Challenges in Cell and Gene Therapy Studies
The benefits of working with an institutional biosafety committee in CGT research.
Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials
Integrated approaches can help enhance recruitment plans.
Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular Dystrophy
Approaches sponsors, CROs, and investigators can take from the DMD experience.
The Risk-Reward Proposition for CGT Clinical Trials
As activity in this space grows, so do the hurdles in moving these products forward.
Philadelphia Shines in Cell and Gene Therapy Research Pursuits
Chamber of Commerce for Greater Philadelphia ranks city No. 2 overall for cell CGT hubs.
Survey Investigates Backup Solution Adoption for ePRO Systems
Survey results emphasize need for flexibility in strategies.
A Pervasive Patient Focus in EU Clinical Trials as New Rules Face Fine-Tuning
New EU clinical trial regulation places heavy importance on patient-submitted documents.
Scientists Don’t Ever Stop Sciencing
Cell and gene therapy space set to advance amid recent therapeutic innovation.
Applied Clinical Trials October 2022 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials October 2022 issue in an interactive PDF format.
Key Clinical Trial Industry Themes Post-COVID
Barbara Lopez Kunz, president, and global chief executive at DIA, discusses key themes on the current state of the clinical trials industry and its future.
Clinical Trial Modernization Raises FDA Compliance Issues
Agency officials express associated concerns around clinical trial data reliability and quality.
What the Future State Really Looks Like for Clinical Data Leaders
Accelerating trends in clinical data are forcing changes in strategy.
